Cure8 research brief
People on biologic therapy who are not responding to standard doses may benefit from dose escalation — this study suggests escalation is common in routine care and linked with improved objective and patient‑reported outcomes and lower healthcare use.
Adults with IBD (including Crohn's disease and ulcerative colitis), clinicians who manage biologic dosing, patients currently on biologics, and health system planners/policymakers concerned with access and funding for dose escalation.
This analysis used data from the CCCare electronic medical record de‑identified clinical quality registry and included 6093 biologic treatment courses, with 37% undergoing dose escalation. Median time to escalation was about 5 months, and most patients remained on escalated doses at 12 months.
Dose escalation was defined as maintenance dosing above the standard average daily dose. Twelve months after escalation, the registry showed improvements in calprotectin, PRO2 scores, and endoscopic remission rates, plus fewer endoscopies, radiology tests, and hospital admissions reported in the dataset.
The authors note that limited formal funding for dose escalation in Australasia may delay escalation and worsen disease control and costs.
This is an observational registry analysis (real‑world data) rather than a randomized trial. Dose escalation was defined by dosing above standard averages in the registry; causality cannot be established and unmeasured confounding may influence outcomes. The article highlights regional funding restrictions that may affect timing of escalation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
